<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04983862</url>
  </required_header>
  <id_info>
    <org_study_id>21-099</org_study_id>
    <nct_id>NCT04983862</nct_id>
  </id_info>
  <brief_title>Fluorescent Imaging of Nerves With Illuminare-1 During Surgery</brief_title>
  <official_title>Phase I Trial of Real-Time Intraoperative Fluorescent Imaging of Nerve Structures Using Illuminare-1, A Novel Myelin-Binding Fluorophore</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Illuminare Biotechnologies</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will test the safety of using Illuminare-1 during standard surgery for prostate&#xD;
      cancer. The study researchers will test increasing doses of Illuminare-1 to find the dose&#xD;
      that makes the nerve structures fluoresce (light up) but causes few or mild side effects.&#xD;
      When the researchers find this dose, it will be tested in new groups of study participants to&#xD;
      see whether surgery performed using Illuminare-1 guidance is better than surgery performed&#xD;
      without intraoperative guidance. The researchers will also do tests to study the way the body&#xD;
      absorbs, distributes, and gets rid of Illuminare-1. This study is the first to test&#xD;
      Illuminare-1 in people. Illuminare-1 has received Fast Track designation from the US FDA.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 4, 2021</start_date>
  <completion_date type="Anticipated">October 4, 2023</completion_date>
  <primary_completion_date type="Anticipated">October 4, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>This is a first-in-human, single-arm, open-label, dose-escalation phase I study to investigate the safety of Illuminare-1, a myelin-binding fluorescent small molecule in patients undergoing routine minimally invasive radical prostatectomy.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>determine the safety of Illuminare-1</measure>
    <time_frame>up to 45 days</time_frame>
    <description>Five patients will be observed at each dose level. If &gt; 20% of patients within a cohort experience a grade 2 or higher adverse event that is considered attributable to the drug and clinically significant, dose escalation will be stopped at that level, and the prior dose level will be considered the MTD. DLTs will be defined using NCI-CTCAE 5.0.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Prostate Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>Illuminare-1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Illuminare-1</intervention_name>
    <description>Illuminare-1 at 3 dose levels in patients undergoing minimally invasive radical prostatectomy and bilateral pelvic lymph node dissection. Three dose levels will be used: 0.25mg/kg, 0.5mg/kg, and 1.0mg/kg. Once the imaging dose of Illuminare-1 is established at a no-DLT level, an expansion cohort of 20 patients will be evaluated at this dose.</description>
    <arm_group_label>Illuminare-1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Karl Storz D-Light C photodynamic diagnostic (PDD)</intervention_name>
    <description>The Storz PDD system will be used as the hardware system in this phase 1 study due to its proven safety profile.</description>
    <arm_group_label>Illuminare-1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18 years or older and capable of signing their own consent form&#xD;
&#xD;
          -  Scheduled for minimally invasive radical prostatectomy with pelvic lymph node&#xD;
             dissection&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior pelvic surgery or pelvic radiation therapy&#xD;
&#xD;
          -  Known central nervous or peripheral nervous system disease or insult (including&#xD;
             neurodegenerative diseases), current use of neurotoxic medications, or use of&#xD;
             cytotoxic chemotherapy with known neurotoxicity within 1 month&#xD;
&#xD;
          -  Exposure to investigational agents in the immediate 30 days before or 15 days after&#xD;
             study drug administration&#xD;
&#xD;
          -  Patients with significant renal dysfunction (&lt;60 mL/min as assessed by the Cockcroft&#xD;
             Gault calculation for creatinine clearance)&#xD;
&#xD;
          -  Exposure to phototoxic drugs such as St. John's wort, griseofulvin, thiazide&#xD;
             diuretics, sulfonylureas, phenothiazines, sulphonamides, quinolones, and&#xD;
             tetracyclines, should be avoided. If safe to discontinue use for at least 48 hours,&#xD;
             patients may participate on this trial but will discontinue use for 24 hours before&#xD;
             and after administration of Illuminare-1.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Prostate cancer</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Timothy Donahue, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Timothy Donahue, MD</last_name>
    <phone>646-422-4567</phone>
    <email>donahuet@mskcc.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Vincent Laudone, MD</last_name>
    <phone>646-888-7087</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)</name>
      <address>
        <city>Basking Ridge</city>
        <state>New Jersey</state>
        <zip>07920</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Timothy Donahue, MD</last_name>
      <phone>646-422-4567</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Monmouth (Limited protocol activities)</name>
      <address>
        <city>Middletown</city>
        <state>New Jersey</state>
        <zip>07748</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Timothy Donahue, MD</last_name>
      <phone>646-422-4567</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Bergen (Limited Protocol Activities)</name>
      <address>
        <city>Montvale</city>
        <state>New Jersey</state>
        <zip>07645</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Timothy Donahue, MD</last_name>
      <phone>646-422-4567</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Commack (Limited Protocol Activities)</name>
      <address>
        <city>Commack</city>
        <state>New York</state>
        <zip>11725</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Timothy Donahue, MD</last_name>
      <phone>646-422-4567</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Westchester (Limited protocol activities)</name>
      <address>
        <city>Harrison</city>
        <state>New York</state>
        <zip>10604</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Timothy Donahue, MD</last_name>
      <phone>646-422-4567</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Timothy Donahue, MD</last_name>
      <phone>646-422-4567</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mskcc.org/mskcc/html/44.cfm</url>
    <description>Memorial Sloan Kettering Cancer Center</description>
  </link>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>July 22, 2021</study_first_submitted>
  <study_first_submitted_qc>July 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 30, 2021</study_first_posted>
  <last_update_submitted>October 21, 2021</last_update_submitted>
  <last_update_submitted_qc>October 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Fluorescent Imaging</keyword>
  <keyword>Illuminare-1</keyword>
  <keyword>Myelin-Binding Fluorophore</keyword>
  <keyword>21-099</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

